Patents by Inventor Keisuke Wakasugi

Keisuke Wakasugi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9205136
    Abstract: Methods of enhancing angiogenesis utilizing carboxy-terminal truncated human tyrosyl-tRNA synthetase (TyrRS) are disclosed. The truncated human TyrRS polypeptides comprise residues 1-364 or residues 1-343 of full length human TyrRS (SEQ ID NO: 2).
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: December 8, 2015
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Patent number: 8796237
    Abstract: The invention provides an isolated nucleic acid encoding a polypeptide capable of inhibiting angiogenesis or neovascularization, wherein the nucleic acid comprises a first polynucleotide sequence comprising a coding sequence at least 95 percent identical to a sequence selected from the group consisting of a polynucleotide SEQ ID NO:6, a polynucleotide that encodes a polypeptide of SEQ ID NO:12, and a polynucleotide that encodes a fragment of the polypeptide of SEQ ID NO:12; and wherein the nucleic acid does not encode for the amino acid sequence of amino acids 71-93 of SEQ ID NO:1. Pharmaceutical compositions, vectors, and methods for inhibiting neovascularization or angiogenesis comprising or utilizing the nucleic acids also are provided.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: August 5, 2014
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander
  • Publication number: 20140127183
    Abstract: Methods of enhancing angiogenesis utilizing carboxy-terminal truncated human tyrosyl-tRNA synthetase (TyrRS) are disclosed. The truncated human TyrRS polypeptides comprise residues 1-364 or residues 1-343 of full length human TyrRS (SEQ ID NO: 2).
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: The Scripps Research Institute
    Inventors: Paul SCHIMMEL, Keisuke WAKASUGI
  • Patent number: 8629253
    Abstract: Nucleic acids encoding tRNA synthetase polypeptides useful for regulating angiogenesis are disclosed. Methods of making and using such nucleic acids are also disclosed.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: January 14, 2014
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Patent number: 8562977
    Abstract: Pharmaceutical compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis an nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: October 22, 2013
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Publication number: 20120263702
    Abstract: Pharmaceutical compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis an nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 18, 2012
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Paul SCHIMMEL, Keisuke WAKASUGI
  • Publication number: 20120238620
    Abstract: The invention provides an isolated nucleic acid encoding a polypeptide capable of inhibiting angiogenesis or neovascularization, wherein the nucleic acid comprises a first polynucleotide sequence comprising a coding sequence at least 95 percent identical to a sequence selected from the group consisting of a polynucleotide SEQ ID NO:6, a polynucleotide that encodes a polypeptide of SEQ ID NO:12, and a polynucleotide that encodes a fragment of the polypeptide of SEQ ID NO:12; and wherein the nucleic acid does not encode for the amino acid sequence of amino acids 71-93 of SEQ ID NO:1. Pharmaceutical compositions, vectors, and methods for inhibiting neovascularization or angiogenesis comprising or utilizing the nucleic acids also are provided.
    Type: Application
    Filed: September 12, 2011
    Publication date: September 20, 2012
    Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander
  • Publication number: 20120122178
    Abstract: The present invention provides an isolated polypeptide comprising residues 94-471 of SEQ ID NO: 10, wherein the isolated polypeptide does not comprise amino acid residues 1-47 of SEQ ID NO: 10. Nucleic acids and expression vectors encoding the peptide also are provided.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 17, 2012
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Patent number: 8148125
    Abstract: Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: April 3, 2012
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Patent number: 8101566
    Abstract: A method of suppressing angiogenesis in a mammal (e.g., for treating tumors, tumor metastasis or a condition that would benefit from decreased angiogenesis) comprises the step of administering to the mammal an angiostatically effective amount of a pharmaceutical composition comprising an isolated antiangiogenic truncated tryptophanyl-tRNA synthetase (TrpRS) polypeptide or an isolated nucleic acid that comprises a polynucleotide sequence that encodes the truncated TrpRS polypeptide. The truncated TrpRS polypeptide comprises residues 71-471 of SEQ ID NO: 10, residues 48-471 of SEQ ID NO: 10, or a polypeptide of approximately 47 kD molecular weight produced by cleavage of the polypeptide of SEQ ID NO: 10 with polymorphonuclear leucocyte elastase.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: January 24, 2012
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Patent number: 8017593
    Abstract: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which includes at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11). A method for assaying the angiogenesis inhibiting activity of a composition is also provided.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: September 13, 2011
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander
  • Publication number: 20110110917
    Abstract: Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
    Type: Application
    Filed: January 17, 2011
    Publication date: May 12, 2011
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Paul SCHIMMEL, Keisuke WAKASUGI
  • Patent number: 7901917
    Abstract: Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: March 8, 2011
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Publication number: 20100158883
    Abstract: A method of suppressing angiogenesis in a mammal (e.g., for treating tumors, tumor metastasis or a condition that would benefit from decreased angiogenesis) comprises the step of administering to the mammal an angiostatically effective amount of a pharmaceutical composition comprising an isolated antiangiogenic truncated tryptophanyl-tRNA synthetase (TrpRS) polypeptide or an isolated nucleic acid that comprises a polynucleotide sequence that encodes the truncated TrpRS polypeptide. The truncated TrpRS polypeptide comprises residues 71-471 of SEQ ID NO: 10, residues 48-471 of SEQ ID NO: 10, or a polypeptide of approximately 47 kD molecular weight produced by cleavage of the polypeptide of SEQ ID NO: 10 with polymorphonuclear leucocyte elastase.
    Type: Application
    Filed: January 6, 2010
    Publication date: June 24, 2010
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Publication number: 20090275643
    Abstract: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which includes at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11).
    Type: Application
    Filed: January 13, 2009
    Publication date: November 5, 2009
    Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander
  • Publication number: 20090227662
    Abstract: Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
    Type: Application
    Filed: April 17, 2009
    Publication date: September 10, 2009
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Patent number: 7521215
    Abstract: Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: April 21, 2009
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Patent number: 7476651
    Abstract: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which includes at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11). A method for assaying the angiogenesis inhibiting activity of a composition is also provided.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: January 13, 2009
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander
  • Patent number: 7413885
    Abstract: The invention provides an isolated nucleic acid encoding a water-soluble polypeptide fragment of human tryptophanyl-tRNA synthetase, which is useful for the inhibition of angiogenesis. The nucleic acid comprises a polynucleotide of SEQ ID NO: 6, a polynucleotide hybridizable to SEQ ID NO: 6, a polynucleotide that encodes the polypeptide of SEQ ID NO: 7, a polynucleotide that encodes a polypeptide of SEQ ID NO: 12, a polynucleotide that encodes a polypeptide epitope of SEQ ID NO: 7, or a polynucleotide that is hybridizable to a polynucleotide that encodes a polypeptide epitope of SEQ ID NO: 7. Vectors and recombinant cells comprising the nucleic acid are also provided.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: August 19, 2008
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander
  • Publication number: 20080064639
    Abstract: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which includes at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11).
    Type: Application
    Filed: September 20, 2007
    Publication date: March 13, 2008
    Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander